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ADAMs (a disintegrin and metalloproteinases) are involved in various biological
events such as cell adhesion, migration and invasion, membrane protein shedding
and proteolysis. However, there have been no systematic studies on the expression
of ADAMs in human ovarian carcinomas. We therefore examined mRNA expression
of all the proteolytic ADAM species including ADAM8, 9, 10, 12, 15, 17, 19, 20, 21,
28, 30, 33 and ADAMDEC1 in human ovarian carcinomas, and found that prototype
membrane-anchored ADAM9m, but not secreted isoform ADAM9s, is significantly
over-expressed in carcinomas than in control non-neoplastic ovarian tissue. Among
the histological subtypes of serous, endometrioid, mucinous and clear cell carcino-
mas, ADAM9m expression was highest in clear cell carcinomas. Immunohistochem-
istry showed that all the clear cell carcinoma samples displayed ADAM9m primarily
on the carcinoma cell membrane. By immunoblotting, ADAM9m was detected mainly
in an active form in the clear cell carcinoma tissues. When two clear cell carcinoma
cell lines (RMG-I and TOV21G cells) with ADAM9m expression were treated with
cisplatin, viability was significantly reduced and apoptosis increased in ADAM9m
knockdown cells compared with mock transfectants. In addition, treatment of the
cells with neutralizing anti-ADAM9m antibody significantly decreased viability com-
pared with non-immune IgG, whereas ADAM9m over-expression significantly
increased viability compared with mock transfectants. Our data show, to the best of
our knowledge, for the first time, that ADAM9m is over-expressed in an activated
form in human ovarian clear cell carcinomas, and suggest that ADAM9m plays a key
role in cisplatin resistance.
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1 | INTRODUCTION
Ovarian carcinomas, the most lethal gynecological malignancy, are
histologically subdivided into serous, endometrioid, mucinous, clear
cell, Brenner (urothelial) and undifferentiated carcinomas.1 These
subtypes show distinct differences not only in microscopic appear-
ance but also in clinical behavior and molecular background.1,2
Among them, clear cell carcinoma is characterized by resistance to
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standard platinum- and taxane-based chemotherapy for ovarian car-
cinomas.3,4 Although the incidence rate of clear cell carcinoma in
Western countries is low ranging from 1% to 12%,3,5 clear cell carci-
noma is the second most common subtype (15%-25%),3,6 following
serous carcinoma (36%) in Japan.6 Clear cell carcinoma patients at
an advanced stage or with recurrent carcinoma usually take an unfa-
vorable course mainly because of chemoresistance,3,4,7 which is
explained by mechanisms such as decreased drug accumulation,
increased drug detoxification, and increased DNA repair activity.7-10
However, the details underlying resistance to chemotherapy in clear
cell carcinoma have not been clarified.
Members of the ADAM (a disintegrin and metalloproteinase)
gene family are multifunctional proteins and involved in various
pathophysiological events such as cell adhesion and migration, cell
fusion, angiogenesis, and cancer cell proliferation and progression.11-13
They are composed of 13 proteolytic ADAMs and eight non-proteo-
lytic ADAMs.11-13 Proteolytic ADAMs are transmembrane proteins
comprising propeptide, metalloproteinase, disintegrin-like, cysteine-
rich, epidermal growth factor (EGF)-like, transmembrane and cyto-
plasmic domains, and share the metalloproteinase domain with that
of matrix metalloproteinases.11,13-15 Some of the members such as
ADAM9, ADAM12 and ADAM28 have short-secreted splice variants
besides prototype membrane-anchored forms: ADAM9s and
ADAM9m (ADAM9-L),16 ADAM12s and ADAM12m (ADAM12-L),17
and ADAM28s and ADAM28m.18 Previous studies on human ovarian
carcinomas showed over-expression of ADAM10,19 ADAM1220 and
ADAM17.21 ADAM10 and ADAM17 are reported to have a key role
in shedding of the adhesion molecule L1 (CD171) and heparin-bind-
ing EGF-like growth factor (HB-EGF), respectively.19,21 ADAM12 is
associated with clinical variables and poor prognosis of patients with
high-grade serous ovarian carcinoma.20 Expression of ADAM9 in
ovarian carcinomas, albeit not significantly different from control, is
also described without any comments on the function.21 However,
there have been no systematic studies on the expression profiles of
ADAM family members in human ovarian carcinomas that are classi-
fied to histological subtypes. In addition, little or no information is
available for the involvement of ADAM species in chemoresistance
in ovarian carcinomas.
In the present study, we examined mRNA expression of all
the proteolytic ADAM members in human ovarian carcinoma tis-
sues, and found that only ADAM9m is significantly over-expressed
in ovarian carcinomas, showing the highest expression in clear cell
carcinoma. Our in vitro experiments also provided data that
ADAM9m is involved in resistance to cisplatin in clear cell carci-
noma cells.
2 | MATERIALS AND METHODS
2.1 | Clinical samples and histology
Ovarian tumor samples (n = 48) from patients with primary ovarian
carcinoma and control ovarian tissues (n = 13) stored in the
Keio Women’s Health Biobank (KWB) in Keio University School of
Medicine were enrolled. All patients underwent surgery at Keio
University Hospital and received no neoadjuvant chemotherapy prior
to surgery. Written informed consent for experimental use of the
samples was obtained from each patient registered in KWB. Ovarian
carcinomas were pathologically classified according to the standard
criteria of WHO histological classification of tumors of female repro-
ductive organs.1 Some parts of the carcinoma samples (n = 35) and
non-neoplastic ovarian samples (n = 7) were snap-frozen, and stored
at 80°C. Control non-neoplastic ovarian tissues were obtained
from contralateral non-neoplastic ovaries in the ovarian carcinoma
patients (n = 6) or from carcinoma-free ovaries in patients who
underwent total hysterectomy and adnexectomy for International
Federation of Gynecology and Obstetrics (FIGO) Stage I uterine cor-
pus carcinoma (n = 7). The study protocol, which complied with the
principles outlined in the Declaration of Helsinki, was approved by
the Keio University School of Medicine Ethics Committee (Nos
20070081 and 20160326).
2.2 | RT-PCR and quantitative real-time PCR
(qPCR)
cDNAs were prepared from isolated total RNA, and subjected to RT-
PCR for examination of the 13 proteolytic ADAM species and
housekeeping gene b-actin (Table S1) as described previously.18 Rel-
ative expression levels of ADAM9m, ADAM10, ADAM15, ADAM17,
ADAM28m and ADAM28s to b-actin were measured by qPCR with
TaqMan probes (ABI Prism7000 Sequence Detection System;
Applied Biosystems, Foster City, CA, USA) (Table S2). Although the
primers for ADAM9 by qPCR detected both ADAM9m and
ADAM9s, the data were considered to reflect ADAM9m expression
as no or negligible expression of ADAM9s was found in all the ovar-
ian carcinoma tissues examined by RT-PCR.
2.3 | Immunohistochemistry
Paraffin sections of the ovarian tissues were subjected to immunos-
taining with goat anti-human ADAM9 polyclonal antibody (AF939;
R&D Systems, Minneapolis, MN, USA) or non-immune goat IgG (AB-
108-C; R&D Systems) after blocking endogenous peroxidase and
antigen retrieval by autoclaving, followed by reactions with biotiny-
lated secondary antibody and 3-30-diaminobenzidine.18,22 Sections
were counterstained with hematoxylin. ADAM9 immunostaining on
cell membranes was scored from 0 to 3+ according to the 2007
ASCO/CAP HER-2/neu immunohistochemical scoring guidelines for
breast cancer.23 Briefly, no membranous immunostaining was scored
0; focal but not circumscribed membranous staining over 10% of
tumor cells 1+; circumscribed membranous staining with moderate
intensity over 10% of tumor cells 2+; and circumscribed membra-
nous staining with strong intensity over 30% of tumor cells 3+. Intra-
cytoplasmic immunostaining was also scored from 0 to 2+ as
follows: score 0 for negative staining; score 1+ for weak staining;
and score 2+ for strong staining. The sum of membranous and intra-
cytoplasmic immunostaining scores was used as total
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immunohistochemical score. MIB1-positive cell index was deter-
mined by immunostaining with anti-Ki-67 antibody (MIB1; DAKO A/
S, Glostrup, Denmark).18
2.4 | Immunoblotting
Homogenate supernatants (50 lg/lane) of 19 ovarian carcinomas or
ovarian carcinoma cell lines (20 lg/lane) were subjected to
immunoblotting with anti-ADAM9 antibody to the C-terminal
domain of human ADAM9m (#2099s; Cell Signaling Technology,
Danvers, MA, USA) or anti-b-actin antibody (A5316; Sigma-Aldrich,
St Louis, MO, USA), followed by reaction with ECL western blot-
ting reagents (Thermo Fisher Scientific, Rockford, IL, USA). Densito-
metric analysis was done using ImageJ software (https://imagej.
nih.gov/ij/).
2.5 | Cell cultures
RMG-I and TOV21G cell lines derived from human ovarian clear cell
carcinomas were used after authentication by JCRB cell bank (Osaka,
Japan; certification number, KBN0352). RMG-I cells were established
by the Obstetric and Gynecologic Department, Keio University
School of Medicine, and TOV21G cells were purchased from ATCC
(Manassas, VA, USA). RMG-I and TOV21G cells were cultured in
RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) and
DMEM/F-12 (Sigma-Aldrich) supplemented with 15% FBS and
antibiotics, respectively.
2.6 | Knockdown of ADAM9 by shRNAs and over-
expression of ADAM9m
The 5 different lentiviral vectors for ADAM9 shRNA and non-targeting
shRNA vectors (mock) were purchased from Sigma-Aldrich. As two of
them (sh1 and sh2) efficiently suppressed the expression, they were
used for the experiments. The encoding sequences of the shRNAs
were as follows: sh1, 50-CCGGAGAGAAGTTCCTATATATCTCGAGA
TATATAGGAACTTCTCTGGGTTTTTG-30; sh2, 50-CCGGGCTAGTTC
TAAAGAAAGGTTTCTCGAGAAACCTTTCTTTAGAACTAGCTTTTTG-30.
Stable transfectants were selected as described previously.22 ADAM9m
was over-expressed in TOV21G cells by transfection with pcDNA3.1
vectors encoding ADAM9m (Clone ID, OHu18124D; Genscript, Piscat-
away, NJ, USA) or mock pcDNA3.1 vectors, and the expression was
examined by RT-PCR.
2.7 | Analyses of migration and activation of EGF
receptor (EGFR)
RMG-I and TOV21G cells transfected with ADAM9m shRNA or
mock vectors were grown to confluence and scratch-wounded with
a 200-lL pipette tip. They were allowed to migrate in the medium
containing 5 and 0.5 mmol/L hydroxyurea (Sigma-Aldrich), respec-
tively. Activation of EGFR in the transfectants was examined by
immunoblotting with anti-phosphoEGFR antibody (sc-12351R; Santa
Cruz Biotechnology, Dallas, TX, USA) or anti-EGFR antibody (sc-03;
Santa Cruz Biotechnology).
2.8 | MTT assay
RMG-I and TOV21G cells transfected with shRNA or mock vectors
were treated with different concentrations of cisplatin (Sigma
Aldrich) ranging from 0 to 50 lmol/L for up to 48 hours, and the
viability was measured using MTT cell count kit (Nacalai Tesque,
Kyoto, Japan). By preliminary experiments, LD50 and treatment
times were determined to be 20 lmol/L for 48 hours for RMG-I
cells and 15 lmol/L for 24 hours for TOV21G cells. They were also
treated with neutralizing anti-human ADAM9 antibody specific to
ectodomain (5 lg/mL, MAB939; R&D Systems)24 or non-immune
mouse IgG (5 lg/mL; BD Biosciences Pharmingen, Franklin Lakes,
NJ, USA) for 1.5 hours prior to cisplatin treatment.
2.9 | Apoptosis assay
shRNA-transfected RMG-I and TOV21G cells were treated with
LD50 concentrations of cisplatin. Both floating cells and detached
cells by trypsin treatment were collected, stained with Annexin V
and propidium iodide (PI) using an Annexin V FITC kit (Medical &
Biological Laboratories, Nagano, Japan), and then subjected to flow
cytometry (XL-MCL; Beckman Coulter, Miami, MA, USA). Results of
flow cytometric analysis were analyzed on FlowJo software (ver.
7.6.5).
2.10 | Statistical analysis
Data between the two independent groups were determined by
Mann-Whitney U test, and results of MTT and apoptosis assays
were calculated by Student’s t test. For comparison of more than
2 groups, values were corrected with Bonferroni’s multiple com-
parison methods. Log-rank test and Kaplan-Meier method were
used for survival analyses. P-values <.05 were considered to be
significant.
3 | RESULTS
3.1 | mRNA expression of proteolytic ADAM
species in human ovarian carcinomas
mRNA expression of ADAM8, ADAM9m, ADAM9s, ADAM10,
ADAM12m, ADAM12s, ADAM15, ADAM17, ADAM19, ADAM20,
ADAM21, ADAM28m, ADAM28s, ADAM30, ADAM33 and ADAM-
DEC1 was screened by RT-PCR in serous (n = 4), endometrioid
(n = 3), mucinous (n = 3) and clear cell carcinomas (n = 4), and con-
trol non-neoplastic ovarian tissues (n = 3). There was no or negligible
expression of ADAM9s, ADAM12s, ADAM33 and ADAMDEC1 in
the carcinoma or the non-neoplastic tissues, and expression of
ADAM8, ADAM12m, ADAM19, ADAM20, ADAM21 and ADAM30
was observed in less than ~50% of the carcinoma samples (Figure 1).
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In contrast, ADAM9m, ADAM10, ADAM15, ADAM17, ADAM28m
and ADAM28s were expressed in more than 70% of the carcinoma
tissues, and the expression of these ADAM species appeared to be
high in the carcinomas and only weak in the non-neoplastic ovarian
tissues (Figure 1). Thus, we further analyzed the expression levels of
these ADAM species in a larger number of ovarian carcinoma and
control ovarian tissues by qPCR.
3.2 | Over-expression of ADAM9m and its
correlations with clinicopathological factors
Expression levels of ADAM9m, ADAM10, ADAM15, ADAM17,
ADAM28m and ADAM28s were compared by setting the average
level in the control samples as 1.0. Among the ADAM species
examined, only the ADAM9m level was significantly 3.1-fold higher
in the carcinoma tissues (3.11  2.52; mean  SD; n = 35) than in
the control non-neoplastic ovarian tissues (1.00  0.40; n = 7)
(P < .01) (Figure 2A). Expression level of ADAM28m appeared to
be higher in the carcinoma samples (4.14  4.94; n = 30) than in
the control samples (1.00  0.64; n = 7), although no significant
difference was obtained between the two groups (P = .068) (Fig-
ure 2A). Expression levels of ADAM10, ADAM15, ADAM17 and
ADAM28s were almost similar between the carcinoma and the con-
trol non-neoplastic samples (Figure 2A). Therefore, we further ana-
lyzed ADAM9m expression levels by focusing on the four
histological subtypes of ovarian carcinomas. As shown in Figure 2B
and Table S3, the level in the clear cell carcinomas (4.52  2.79;
n = 13), all the samples of which expressed ADAM9m, was the
highest, and significantly higher than that in the control group
(1.00  0.40; n = 7). The levels were also significantly higher in the
endometrioid (2.22  0.93; n = 6) and mucinous carcinomas
(3.68  3.51; n = 5), but not in the serous carcinomas
(1.67  1.19; n = 11), than in the control group (Figure 2B;
Table S2). Expression of ADAM9m was significantly ~2-fold higher
in the clear cell carcinomas (4.52  2.79; n = 13) than in the non-
clear cell carcinomas (2.27  1.97; n = 22) (P < .01) (Figure 2C).
ADAM9m expression level was also significantly higher in Grade 3
ovarian carcinomas (3.91  2.69; n = 17) than in Grade 1/2 carci-
nomas (2.36  2.16; n = 18) (P < .05) (Table S3). However, no posi-
tive correlations were observed between the expression levels of
ADAM9m, ADAM10, ADAM15, ADAM17, ADAM28m and
ADAM28s and clinicopathological parameters including age at oper-
ation, vascular and/or lymphatic invasion, lymph node metastasis,
MIB1-positive cell index and clinical stages of the disease (Table S3
and data not shown for ADAM10, ADAM15, ADAM17, ADAM28m
or ADAM28s). In contrast, overall survival tended to be shorter in
the ADAM9m-high patient group than in the ADAM9m-low group
(log-rank test, P = .0594; Figure S1).
3.3 | Protein expression of ADAM9m in ovarian
carcinoma and non-neoplastic ovarian tissues
Immunohistochemistry with anti-ADAM9m antibody showed that
ADAM9m was positively stained in the cytoplasm and/or on the
cell membrane in 94% of the ovarian carcinoma samples (45/48
cases), whereas the control non-neoplastic ovarian tissues (6
cases) showed negligible immunostaining in the ovarian surface
epithelial cells (Figure 3). No obvious immunostaining of
F IGURE 1 RT-PCR analysis of all the
proteolytic ADAM (a disintegrin and
metalloproteinases) species in the four
ovarian carcinoma subtypes and control
non-neoplastic ovarian tissues. Positive
control for each ADAM species shows RT-
PCR using mRNAs isolated from various
human carcinoma cell lines
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ADAM9m was observed in stromal cells of the carcinoma or
control ovarian tissues, and non-immune IgG showed only back-
ground staining (Figure 3). Intracytoplasmic staining was observed
in 71.4% of the serous carcinomas (10/14 cases), in 94.4% of
the clear cell carcinoma (17/18 cases) and in 100% of the
endometrioid carcinomas (10/10 cases) and the mucinous carci-
nomas (6/6 cases). Although the non-clear cell carcinomas had a
weak and diffuse intracytoplasmic staining pattern (intensity score
1+), most of the clear cell carcinomas showed intracytoplasmic
staining with a strong and coarse granular pattern (intensity
score 2+) (Figure 3). Importantly, all the clear cell carcinomas
(18/18 cases) showed membranous staining, which was charac-
terized by focal membranous staining (membrane score 1+) (50%;
9/18 cases), circumscribed membranous staining with moderate
intensity (membrane score 2+) (39%; 7/18 cases) or circum-
scribed membranous staining with strong intensity (membrane
score 3+) (11%; 2/18 cases) (Figure 3). However, all cases of
serous, endometrioid and mucinous carcinomas, with an excep-
tion of one mucinous carcinoma case, showed only focal circum-
scribed membranous staining (membrane score 1+) at the apical
sites of glandular structures or no membranous staining (mem-
brane score 0) (Figure 3).
When intensity score, membrane score and total score of
ADAM9m were compared among the histological subtypes, all the
scores appeared to be higher in the clear cell carcinomas (Figure 4A,
C,E). Intensity, membrane and total scores were significantly higher
in the clear cell carcinomas than in the non-clear cell carcinomas
(P < .05 or P < .001) (Figure 4B,D,F). Total score of the ADAM9m
immunostaining was also significantly higher in the G3 ovarian carci-
nomas compared with the G1/2 carcinomas (P < .01) (Table S4).
However, there were no significant differences of the immunostain-
ing scores in other clinicopathological parameters including age at
operation, vascular and lymphatic invasion, nodal involvement,
MIB1-positive cell index and FIGO stages of the disease between
F IGURE 2 Quantitative real-time PCR
(qPCR) analysis of the relative mRNA
expression levels of ADAM (a disintegrin
and metalloproteinase) species screened by
RT-PCR and the expression levels of
ADAM9m in four ovarian carcinoma
subtypes. A, Expression levels of
ADAM9m, ADAM10, ADAM15, ADAM17,
ADA28m and ADAM28s in ovarian
carcinoma and control non-neoplastic
ovarian tissues. B, Expression levels of
ADAM9m in ovarian carcinoma subtypes
and control non-neoplastic ovarian tissue.
C, Expression levels of ADAM9m between
non-clear cell and clear cell carcinomas.
Bars indicate mean values. *P < .05;
**P < .01; NS, not significant
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the low-ADAM9 and the high-ADAM9 groups of clear cell carcinoma
(data not shown).
ADAM9m protein expression in ovarian carcinoma tissues was
confirmed by immunoblotting. Active ADAM9m of 74 kDa and/or
precursor form of ADAM9m of 100 kDa were detected in 15 of 19
carcinoma tissues, whereas no definite immunoreactive bands were
obtained with non-immune rabbit IgG (Figure S2A). Densitometric
analysis of the immunoreactive bands showed that relative expres-
sion levels of ADAM9m were significantly higher in the clear cell
carcinomas compared with the non-clear cell carcinomas (P < .05)
(Figure S2B).
3.4 | Knockdown, blocking or over-expression of
ADAM9m and their influences on cisplatin resistance
in ovarian clear cell carcinoma cell lines
As clear cell carcinoma is commonly resistant to platinum-based
chemotherapy,3,7 we studied the possible involvement of
ADAM9m on cisplatin resistance using human ovarian clear cell
carcinoma cell lines, RMG-I and TOV21G cells. They expressed
ADAM9m, ADAM10 and ADAM17, but not ADAM9s (Figure 5A).
When the expression of ADAM9m was knocked down by shRNAs
for ADAM9 (sh1 and sh2), ADAM9m protein expression was
effectively reduced in RMG-Ish1 (44.7%  12.2%), RMG-Ish2
(49.4%  9.0%), TOV21Gsh1 (10.7%  8.8%) and TOV21Gsh2
(47.6%  22.8%) cells as compared to their mock transfectants
(Figure 5B), although no changes in the expression of ADAM10 or
ADAM17 were seen (Figure 5A). We first examined cell migration
and EGFR phosphorylation, and found that cell migration activity
was significantly increased in shRNA transfectants of both RMG-I
and TOV21G cells compared with Mock transfectants (Figure 5C).
In contrast, EGFR phosphorylation was significantly decreased in
RMG-Ish1 and RMG-Ish2 cells compared with Mock transfectants
(Figure 5D). A similar finding was seen in TOV21Gsh1 and
TOV21Gsh2 cells, although no significant difference was obtained
with the TOV21Gsh2 cells (Figure 5D).
When these cells were treated with cisplatin at LD50 concentra-
tions for each cell line, cell viability by MTT assay was significantly
decreased in RMG-Ish1 (21.2%  9.4%) and RMG-Ish2
(31.4%  6.3%) compared with RMG-IMock (51.5%  6.4%)
(P < .001) (Figure 6A). Similar results were obtained with TOV21Gsh1
(21.4%  5.6%) and TOV21Gsh2 cells (25.7%  9.4%) compared
F IGURE 3 Immunohistochemical
localization of ADAM9 in ovarian serous,
endometrioid, mucinous, and clear cell
carcinomas and control non-neoplastic
ovarian tissue. Insets show high-power
view of the rectangle areas of ADAM9
immunostaining. NI, negative control with
non-immune IgG. Bar, 50 lm. Note the
intense and circumscribed membranous
staining with granular intracytoplasmic
staining of ADAM9 in the clear cell
carcinoma. ADAM, a disintegrin and
metalloproteinase
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with TOC21GMock cells (50.3%  7.5%) (P < .001) (Figure 6A). Flow
cytometric analysis indicated that numbers of Annexin V-positive
and PI-positive cells (apoptotic cells) after cisplatin treatment were
significantly increased in RMG-Ish1 (43.8%  6.2%) and RMG-Ish2
(40.9%  2.7%) cells compared to RMG-IMock cells (25.0%  2.6%)
(P < .001) (Figure 6B). TOV21G cells also showed an increase in
numbers of apoptotic cells in TOV21Gsh1 (58.7%  16.1%) and
TOV21Gsh2 cells (48.5%  12.1%) compared to TOV21GMock cells
(19.7%  5.5%) (P < .01) (Figure 6B). We then examined the effect
of anti-ADAM9 antibody specific to the ectodomain of ADAM9m or
ADAM9m over-expression on cisplatin cytotoxicity. The anti-
ADAM9 antibody treatment significantly reduced the viability of
RMG-I cells (24.6%  7.7%) compared with non-immune IgG-treated
cells (48.0%  4.2%) and in TOV21G cells (22.1%  2.8%) compared
with non-immune IgG-treated cells (46.0%  5.7%) (P < .001) (Fig-
ure 6C). However, the viability of cisplatin-treated TOV21G cells
transfected with ADAM9m expression vectors (70.2%  13.6%) was
significantly higher than Mock transfectants (43.0%  8.4%)
(P < .01) (Figure 6D).
4 | DISCUSSION
In the present study, we have shown, to the best of our knowledge,
for the first time, that active ADAM9m is over-expressed on carci-
noma cell membranes in human ovarian clear cell carcinomas. Previ-
ous studies have shown that ovarian carcinomas over-express
ADAM10,19 ADAM12,20 and ADAM17.21 ADAM12 is reportedly
highly expressed by high-grade serous carcinomas,20 but no data on
the histological subtype-specific expression of ADAM10 and
ADAM17 are available.19,21 Although Tanaka et al21 described the
expression of ADAM9, albeit not significantly different from the con-
trol, in ovarian cancers, the study provided no information about the
expression profiles of ADAM9 in the 4 histological subtypes. In con-
trast, in the present study, we found that among the proteolytic
ADAM species, only ADAM9m expression was significantly higher in
the carcinomas, especially in the clear cell carcinomas than in the
control samples. Reasons for the different expression profiles of
these ADAM species are not clear at the present time. However, our
data on the higher-level expression of ADAM9m in the carcinomas
F IGURE 4 Intensity, membrane, and
total scores of ADAM9 immunostaining in
ovarian serous, endometrioid, mucinous,
and clear cell carcinomas. A,C,E,
Distribution of the intensity (0, 1+ and 2+),
membrane (0 to 3+) and total scores (0 to
5+) of ADAM9 immunostaining. B,D,F,
Distribution of the intensity, membrane
and total scores of ADAM9
immunostaining in non-clear cell and clear
cell carcinoma groups. *P < .05;
***P < .001. ADAM, a disintegrin and
metalloproteinase
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may be ascribed, at least in part, to the high percentage of clear cell
carcinoma cases in our samples (13 cases of total 35 ovarian carci-
noma cases).
Epithelial ovarian carcinomas can be classified into major types
designated as type I and type II carcinomas according to the
distinctive clinicopathological and molecular genetic features.1,2,25
Type I carcinomas are composed of low-grade serous, low-grade
endometrioid, clear cell and mucinous carcinomas and are relatively
stable genetically, whereas type II carcinomas comprise high-grade
serous, high-grade endometrioid, malignant mixed mesodermal
F IGURE 5 Knock-down of ADAM9m in human ovarian clear cell carcinoma cell lines (RMG-I and TOV21G) and its effect on cell migration
and EGFR activation. A, mRNA expression of ADAM9m, ADAM9s, ADAM10 and ADAM17 in cells transfected with shRNAs (sh1 and sh2) for
ADAM9 or non-targeting shRNA (Mock) vectors by RT-PCR. b-actin, a loading control. B, Protein expression of ADAM9m in cells transfected
with sh1, sh2 or Mock vectors by immunoblotting. C, Migration assay of cells transfected with sh1, sh2 or Mock vectors. Migration activity
was measured at 24 h after scratch-wounding. D, Activation of EGFR of cells transfected with sh1, sh2 or Mock vectors. Expression of
phosphorylated EGFR (pEGFR) and EGFR was examined by immunoblotting. All assays were carried out in triplicate, and repeated 3 times.
Bars, mean value  SD. **P < .01; ***P < .001; NS, not significant. ADAM, a disintegrin and metalloproteinase
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tumors (carcinosarcomas) and undifferentiated carcinomas and all of
them are aggressive, having a very high frequency of TP53 muta-
tions.1,2,25 Interestingly, high-level expression of ADAM9m was clo-
sely related to type I carcinomas (ie, clear cell, mucinous, and
endometrioid carcinomas) in the present study. No or little informa-
tion is available for the molecular mechanism of ADAM9m gene
expression in ovarian carcinomas. However, our previous study on
oncogene-transformed MDCK cells has shown that gene expression
of ADAM9, ADAM10, ADAM12 and ADAM28 is induced by onco-
gene-modulated transformation.26 As type I ovarian carcinomas are
characterized by specific mutations such as ARID1A, PIK3CA, KRAS,
BRAF and PTEN, which target several cell signaling pathways, and
develop in a stepwise way from precursor lesions,25 it is possible to
speculate that the cell signaling pathways caused by these mutations
may trigger ADAM9m gene expression after transformation to type I
ovarian carcinomas. In contrast, in prostate carcinoma cell lines,
exposure of the cells to stress conditions such as cell crowding,
hypoxia, and hydrogen peroxide is known to promote ADAM9
expression, and reactive oxygen species (ROS) and/or hydrogen per-
oxide generated by the cell stress are thought to be responsible for
the expression.27 Reactive oxygen species (ROS) reportedly serves as
a common downstream mediator for androgen- or serum starvation-
induced ADAM9 expression in androgen receptor-positive prostate
carcinoma cells.28 Hydrogen peroxide is also known to promote the
expression of ADAM9 in A549 lung adenocarcinoma cells.24 Ovarian
clear cell and endometrioid carcinomas are frequently associated
with endometriosis10,29,30 and the majority of them are considered
to arise from pre-existing endometriosis under the tissue microenvi-
ronment with severe iron-induced oxidative stress.31,32 Therefore,
iron-induced ROS may be implicated in the stimulation of ADAM9m
expression in ovarian clear cell and endometrioid carcinomas. How-
ever, further studies are definitely needed to demonstrate the
hypothesis on ADAM9m over-expression in ovarian carcinomas.
Previous studies have shown over-expression of ADAM9 in vari-
ous human carcinomas including breast,33 lung,34 prostate,35 stom-
ach,36 pancreas,37 liver,38 and kidney cancers,39 although most of
these studies did not analyze the expression by focusing on its iso-
forms (ie, ADAM9m and ADAM9s). A recent study on human breast
carcinoma tissues and cell lines disclosed that ADAM9m and
ADAM9s play distinct roles in carcinoma cell migration by inhibiting
and promoting the migration, respectively.16 In the present study,
we confirmed the inhibitory effect of ADAM9m on cell migration.
ADAM9s is known to enhance adhesion of A549 lung adenocarci-
noma cells to cultured endothelial cells and increase Matrigel inva-
sion through binding to b1 integrin, showing the stimulative effect
on cancer cell dissemination.24 In the metastasis of colon carcinoma
cells, ADAM9s expressed by hepatic stellate cells is reported to bind
to a6b4 and/or a2b1 integrins of colon carcinoma cells and enhance
carcinoma cell invasion through digestion of laminin in the liver.40
One of the characteristics of ovarian clear cell carcinomas is rela-
tively slow growth3,4 and disease is presented at early stages.3,4,10,41
Taken together, over-expression of ADAM9m, but not ADAM9s,
seems to be in accordance with the less aggressive character of
ovarian clear cell carcinomas at least in the early stages. Our results
that ADAM9m expression showed no correlations with clinicopatho-
logical factors including MIB-1-positive cell index, lymphatic and vas-
cular invasion, metastasis and clinical stages suggest that ADAM9m
expressed by ovarian clear cell carcinoma cells plays a role different
from cancer cell proliferation, invasion or metastasis.
Ovarian clear cell carcinomas are known to be mostly resistant
to chemotherapy, and this chemoresistance is a major reason for the
poor prognosis of patients with ovarian clear cell carcinoma.4,7,10,41
Numerous cellular mechanisms contributing to resistance to
chemotherapeutic drugs such as cisplatin have been proposed,
including changes in cellular uptake and/or efflux of drugs, increased
detoxification, inhibition of apoptosis and increased DNA repair.4,7,10
As reducing cisplatin accumulation by cancer cells seems to be a
major form of the resistance42 and multi-drug resistance genes such
as MDR-1, MRP-1, MRP-2 and ABCF2 are involved in efflux of cis-
platin from the cells in many carcinoma cells including ovarian clear
cell carcinoma cells,7,43 we first examined the effect of ADAM9m on
the expression of these multi-drug resistance genes by knocking
down ADAM9m expression by shRNAs in ovarian clear cell carci-
noma cell lines, and found no changes in their expression (Ueno M.,
et al., unpublished data). Therefore, we then examined the effect on
cell viability in cisplatin-treated clear cell carcinoma cells and showed
that knock-down of ADAM9m or inhibition of ADAM9m activity
increases apoptotic cells, indicating enhancement of sensitivity to
cisplatin in clear cell carcinoma cells. Similar effect of ADAM9 on
resistance to chemotherapeutic drugs and radiation has been
reported by siRNA-driven ADAM9 knock-down experiments in pros-
tate carcinoma cells.44 The authors in the study suggested that
ADAM9 plays a role in therapeutic resistance by altering E-cadherin
and integrin expression.44 In colorectal carcinoma cell lines,
chemotherapy-induced activation of ADAM17 is known to con-
tribute to chemoresistance to 5-fluorouracil by transactivation of
EGF receptor (EGFR) through shedding of EGFR ligands such as
transforming growth factor-a.45 Shedding of HB-EGF by ADAM17,
ADAM9 and/or ADAM10 is also suggested to be related to resis-
tance to doxorubicin in bladder and lung carcinoma cells.46 In addi-
tion, a recent study on stomach carcinoma cell lines provided
evidence that ADAM9 plays a role in EGFR transactivation through
shedding of EGFR ligands.47 In the present study, we provided data
that EGFR activation is down-regulated by knock-down of ADAM9m
expression. We also showed that ADAM9m exists on clear cell carci-
noma cell membranes in an activated form and showed that knock-
down of ADAM9m with shRNAs or inhibition of the activity with
neutralizing anti-ADAM9m antibody enhances chemosensitivity to
cisplatin and ADAM9m over-expression increases chemoresistance
in ovarian clear cell carcinoma cells. Altogether, the data suggest that
the activity of ADAM9m confers cisplatin resistance probably
through the EGFR ligand shedding/EGFR activation axis, although
further studies on the molecular mechanisms are necessary.
In conclusion, we have shown over-expression of ADAM9m in
human ovarian clear cell carcinomas, and provided evidence that
ADAM9m expressed on carcinoma cell membranes is involved in
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F IGURE 6 Effects of ADAM9m knock-down, inhibition of ADAM9m activity and ADAM9m over-expression on ovarian clear cell carcinoma
cells after treatment with cisplatin. A, ADAM9m knock-down effect on cell viability after treatment with cisplatin. Viability of RMG-I and
TOV21G cells treated without (CDDP) or with cisplatin (CDDP+) was evaluated by MTT assay. B, Effect of ADAM9m knock-down on
cisplatin-induced apoptotic cell death. Apoptotic cells showing positive reaction of propidium iodide (PI) and Annexin-V in Mock and ADAM9m
shRNA transfectants (sh1 and sh2) were monitored by flow cytometric assay. C, Effect of neutralizing anti-ADAM9m antibody on cisplatin-
treated cells. Viability of the cells treated with LD50 concentration of cisplatin in the presence of non-immune IgG (NI) or anti-ADAM9m
antibody (aADAM9) was evaluated by MTT assay. Cont, the cells treated with LD50 cisplatin alone. D, ADAM9m over-expression effect on
cisplatin-treated cells. mRNA expression and cell viability of TOV21G cells transfected with ADAM9m expression vectors (A9m-t) or mock
vectors (Mock) were examined by RT-PCR and MTT assay, respectively. All assays were carried out in triplicate, and repeated 3 times. Bars,
mean value  SD. NS, not significant; *P < .05; **P < .01; ***P < .001. ADAM, a disintegrin and metalloproteinase
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cisplatin resistance of clear cell carcinoma cells. These findings sug-
gest that ADAM9m could be an attractive target for therapies of
ovarian clear cell carcinomas when combined with established
chemotherapeutics such as cisplatin.
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